Is dasatinib a chemo drug?

SPRYCEL is the trade name for the generic chemotherapy drug Dasatinib. In some cases, health care professionals may use the trade name SPRYCEL when referring to the generic drug name Dasatinib. Drug Type: SPRYCEL is a targeted therapy.

Why does dasatinib lose effectiveness?

The most common reasons for discontinuation were study-drug toxicity (QD: 29%; BID: 36%) or disease progression (QD: 27%; BID: 23%). The median duration of dasatinib for patients with CML-AP was 15 months (QD) or 13 months (BID) at the 5-year cutoff (Table 1).

What does dasatinib bind to?

Unlike most RTK inhibitors, Dasatinib binds the active conformation of BCR-Abl. Is used to treat patients with certain Imatinib resistant forms of CML.

Which is one of the main targets of dasatinib?

Dasatinib is an ATP-competitive protein tyrosine kinase inhibitor. The main targets of dasatinib are BCR/Abl (the “Philadelphia chromosome”), Src, c-Kit, ephrin receptors, and several other tyrosine kinases.

What kind of kinase inhibitor is dasatinib anhydrous?

Dasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor. Dasatinib Anhydrous is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases.

What is the PDB 2gqg of dasatinib?

Information about this risk has been added to the Warnings and Precautions section of the Sprycel drug label. Crystal structure ( PDB 2GQG) of Abl kinase domain (blue) in complex with dasatinib (red). Dasatinib is an ATP-competitive protein tyrosine kinase inhibitor.

Why is dasatinib more effective than imatinib in CML?

Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.